1SCHWARTZ R N. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols [ J ]. Am J Health-Syst Pharm, 2007, 64 ( 1 ) : S5-S13.
2LUDWIG H, VAN BELLE S, BARRETT-LEE P, et al. The European Cancer Anaemia Survey (ECAS) : a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients[ J]. Eur J Cancer, 2004, 40 (15) : 2293-306.
3陈灏珠,主编.实用内科学[M]第12版.北京:人民卫生出版社,2005.1 231-1 245.
4PRONZATO P. Cancer-related anaemia management in the 21st century[J]. Cancer Treat Rev, 2006, 32(Suppl 2) : S1-S3.
5BOHLIUS J, WILSON J, SEIDENFELD J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9 353 patients [ J ]. J Natl Cancer Inst, 2006, 98(10) :708-714.
6BOHLIUS J, LANGENSIEPEN S, SCHWARZER G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis[ J]. J Natl Cancer Inst, 2005, 97(7):489-498.
7HENRY D H, DAHL N V, AUERBACH M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy [ J ]. Oncologist, 2007, 12 ( 2 ) :231-242.
